kabutan

SymBio Pharmaceuticals Limited(4582) Summary

4582
TSE Growth
SymBio Pharmaceuticals Limited
92
JPY
0
(0.00%)
Apr 28, 3:30 pm JST
0.57
USD
Apr 28, 2:30 am EDT
Result
PTS
outside of trading hours
91.5
Apr 28, 11:37 pm JST
Summary Chart Historical News Financial Result
PER
PBR
7.18
Yield
ー%
Margin Trading Ratio
11,263.25
Stock Price
Apr 28, 2026
Opening Apr 28, 9:00 am
92 JPY 0.57 USD
Previous Close Apr 27
92 JPY 0.57 USD
High Apr 28, 10:48 am
94 JPY 0.58 USD
Low Apr 28, 9:03 am
91 JPY 0.57 USD
Volume
486,200
Trading Value
0.05B JPY 0.28M USD
VWAP
92.26 JPY 0.58 USD
Minimum Trading Value
9,200 JPY 57 USD
Market Cap
6.65B JPY 0.04B USD
Number of Trades
278
Liquidity & Number of Trades
As of Apr 28, 2026
Liquidity
Slightly High
1-Year Average
782
1-Year High Feb 20, 2026
28,273
Margin Trading
Date Short Interest Long Margin Positions Ratio
Apr 24, 2026 0 6,171,800
Apr 17, 2026 0 6,034,100
Apr 10, 2026 0 6,086,700
Apr 3, 2026 0 6,346,300
Mar 27, 2026 0 6,428,500
Company Profile
SymBio Pharmaceuticals Limited specializes in three areas: cancer, hematology, and pain management. The company also commercializes new drug candidates from other companies.
Sector
Pharmaceuticals
SymBio Pharmaceuticals Limited is a specialty pharmaceutical company focused on rare diseases, primarily in the fields of oncology, hematology, and viral infections. The company advances the development of compounds that have already established proof of concept in humans. Utilizing its unique discovery network and evaluation expertise, SymBio conducts initial screenings through its in-house specialist staff, followed by rigorous evaluations from experienced external experts before finalizing potential in-licensing candidates. By adopting a "labo-less fab-less" strategy to minimize fixed costs, the company concentrates on high-value-added activities while outsourcing routine development tasks. SymBio's pipeline includes drugs such as Treakisym, rigosertib, and brincidofovir, promoting new drug development in areas with high unmet medical needs. While the company has primarily focused its business operations in Japan and Asia, it now aims to expand globally to enhance its business value.